Valley Health Earns National Obesity Medicine Accreditation
August 12, 2025 / Obesity medicine accreditation / Valley Health bariatric program / Non-surgical weight loss care / Comprehensive obesity treatment / ACS designation
Valley Health’s Metabolic and Bariatric Program earned ACS Obesity Medicine accreditation, recognizing excellence in comprehensive, evidence-based, non-surgical obesity care. Services include medical evaluations, counseling, medications, and multidisciplinary support, reinforcing obesity as a chronic disease requiring structured, long-term management.
Living at high altitude may help ward off obesity
August 14, 2025 / High altitude obesity / Childhood obesity prevention / Pediatric obesity research / Energy expenditure hypoxia / Colombia health study
A study of over 4 million Colombian children suggests high-altitude living may reduce obesity risk, likely due to increased energy expenditure from lower oxygen levels, extending previous adult-focused research to pediatric populations.
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
August 15, 2025 / Eli Lilly obesity drugs / AI drug discovery / GPCR obesity treatments / Superluminal Medicines partnership / Cardiometabolic disease innovation
Eli Lilly signed a $1.3B deal with Superluminal Medicines to use AI-driven GPCR drug discovery for obesity and cardiometabolic diseases, strengthening its market position beyond GLP-1 therapies with next-generation small-molecule treatments.
UBC Okanagan Study Reveals Individual Differences in How Fasting Impacts the Body
Aug 16, 2025 / Fasting metabolic effects / Obesity immune response / Ketogenic diet research / UBC Okanagan study / Individual fasting differences
A UBC Okanagan study shows fasting affects metabolism and immune function differently in people with obesity versus lean individuals, revealing distinct hormonal, inflammatory, and T-cell responses that challenge assumptions about universal benefits of fasting and ketogenic adaptation.
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
August 14, 2024 / Eli Lilly AI partnership / Obesity drug discovery / GPCR small molecules / Superluminal Medicines deal / Cardiometabolic disease treatments
Eli Lilly entered a $1.3B partnership with Superluminal Medicines to leverage AI in discovering GPCR-targeting small-molecule therapies for obesity and cardiometabolic diseases, expanding beyond GLP-1 drugs and reinforcing its leadership in the rapidly growing obesity treatment market.
Superluminal joins a $1.3B deal with series A backer Lilly
August 18, 2025 / Superluminal Lilly deal / Obesity drug development / GPCR cardiometabolic therapies / AI drug discovery / $1.3B pharma partnership
Superluminal Medicines and Eli Lilly announced a $1.3B collaboration to develop obesity and cardiometabolic therapies targeting GPCRs, combining AI-driven discovery with Lilly’s development expertise, and positioning both companies at the forefront of next-generation metabolic treatments.
Skye Bioscience’s Nimacimab: A New Frontier in Obesity Treatment and a Strategic Buy Opportunity
August 17, 2025 / Skye Bioscience nimacimab / CB1 obesity treatment / Durable weight loss therapy / Obesity drug pipeline / Next-generation obesity medicines
Skye Bioscience’s nimacimab, a first-in-class peripheral CB1 inhibitor, shows promise in obesity treatment by reducing weight rebound, preserving lean mass, and enhancing combination therapy potential, with Phase 2a data expected in 2025 to validate its clinical differentiation.
Heart failure deaths on rise – but new treatments are available
August 14, 2025 / Heart failure treatment / Rising cardiovascular deaths / Obesity and heart disease / Metabolic syndrome risks / New cardiac therapies
Heart failure deaths are rising in the U.S., driven by obesity, diabetes, and hypertension. While risk factors are growing, new drug therapies, devices, and preventive strategies offer hope in reducing hospitalizations and improving long-term outcomes.
FDA Approval Expands Novo Nordisk’s Wegovy to the Fatty Liver Disease MASH
August 18, 2025 / Wegovy FDA approval / MASH liver disease treatment / GLP-1 obesity drug / Novo Nordisk semaglutide / Fatty liver disease therapy
The FDA granted accelerated approval for Novo Nordisk’s Wegovy to treat MASH with moderate-to-severe fibrosis, marking the second approved therapy for this liver disease. Wegovy’s GLP-1 mechanism reduces fat and inflammation, complementing its obesity and cardiovascular indications.
Wegovy Approved for MASH With Fibrosis, No Cirrhosis
August 18, 2024 / Wegovy MASH approval / Semaglutide liver fibrosis / FDA obesity drug expansion / ESSENCE phase 3 trial / Novo Nordisk metabolic therapy
The FDA granted accelerated approval for Novo Nordisk’s Wegovy to treat MASH with stage II–III fibrosis, showing significant improvements in liver inflammation and fibrosis at 72 weeks in the ESSENCE trial, reinforcing semaglutide’s expanding metabolic disease role.
Dysregulation of GTPase-activating protein-binding protein1 in the pathogenesis of metabolic dysfunction-associated steatotic liver disease
August 14, 2025 / G3BP1 liver disease / MASLD MASH mechanisms / Autophagy dysregulation obesity / TFE3 lipid metabolism / Metabolic liver therapy target
Research identifies reduced G3BP1 as a driver of MASLD and MASH progression by impairing autophagy, enhancing lipogenesis, and disrupting TFE3 signaling. Findings suggest G3BP1 as a promising therapeutic target for metabolic liver disease intervention.
Novo Nordisk’s Wegovy gets accelerated US approval for liver disease MASH
August 15, 2025 / Wegovy MASH approval / GLP-1 liver disease therapy / Novo Nordisk obesity drug / FDA metabolic disease decision / Steatohepatitis treatment option
The FDA granted accelerated approval for Novo Nordisk’s Wegovy as the first GLP-1 therapy for MASH with fibrosis, expanding its metabolic disease role and offering a new treatment option alongside lifestyle changes to prevent liver disease progression.
FDA Approves Semaglutide to Treat MASH With Moderate to Advanced Fibrosis
August 18, 2025 / Semaglutide FDA approval / Wegovy MASH treatment / GLP-1 liver fibrosis / ESSENCE phase 3 trial / Metabolic liver disease therapy
The FDA approved semaglutide (Wegovy) as the first GLP-1 therapy for MASH with moderate-to-advanced fibrosis, based on ESSENCE trial results showing significant improvements in steatohepatitis resolution, fibrosis reduction, and weight loss, marking a major advance in metabolic liver disease treatment.
High metabolic syndrome severity linked to development of CKD
August 15, 2025 / ‘Metabolic syndrome severity / Chronic kidney disease risk / cMetS-S trajectory study / CKD prevention strategy / Kidney disease metabolism
A population study found that high metabolic syndrome severity (cMetS-S) significantly increases chronic kidney disease risk, even in non-obese, normoglycemic, and nonhypertensive individuals, highlighting the value of monitoring metabolic health trajectories for early CKD prevention.
Gender-specific associations of metabolic and circadian syndromes with melanoma risk: insights from NHANES 2007–2018
August 18, 2025 / Metabolic syndrome melanoma / Circadian disruption cancer risk / Gender differences melanoma / NHANES melanoma study / MetS CircS associations
NHANES data show metabolic and circadian syndromes increase melanoma risk, with stronger associations in men. MetS components demonstrated dose-response effects, while triglyceride-glucose index was more predictive in women, underscoring sex-specific metabolic and circadian influences on melanoma development.
High Metabolic Syndrome Severity Linked to Development of CKD
August 15, 2025 / Metabolic syndrome severity / Chronic kidney disease risk / cMetS-S monitoring / Kidney disease prevention / Metabolic health management
A population-based study found high metabolic syndrome severity (cMetS-S) significantly increases chronic kidney disease risk, even in individuals without obesity, hypertension, or diabetes. Monitoring cMetS-S could support earlier CKD prevention and improve long-term metabolic health management.
FDA Approves Wegovy for Treating Metabolic-Associated Steatotic Hepatitis
August 18, 2025 / Wegovy FDA approval / MASH liver treatment / Semaglutide obesity drug / Metabolic liver disease therapy / Steatohepatitis clinical trial
The FDA approved Wegovy for treating metabolic-associated steatotic hepatitis (MASH), expanding its role beyond weight loss. Clinical trials showed semaglutide reduces liver fat and improves inflammation and fibrosis, offering a new therapeutic option for this obesity-linked liver disease.
Lifestyle changes can greatly improve fatty liver disease
August 12, 2025 / Fatty liver lifestyle changes / NAFLD prevention treatment / NASH liver disease risk / Metabolic syndrome obesity link / Reversing liver fibrosis
Lifestyle changes, including diet and exercise, are key to managing and potentially reversing non-alcoholic fatty liver disease (NAFLD). Linked to obesity and metabolic syndrome, NAFLD can progress to NASH, cirrhosis, or cancer, though early intervention offers significant benefits.
Dietary formaldehyde: a silent aggravator of diabetes and cognitive impairments
August 19, 2025 / Dietary formaldehyde diabetes / Insulin resistance mechanisms / Cognitive decline metabolic link / NMDA receptor impairment / Formaldehyde scavenger therapy
Research links dietary formaldehyde to worsening diabetes and cognitive decline by driving insulin resistance, altering insulin receptor function, and impairing NMDA signaling. Formaldehyde scavengers may represent a novel therapeutic strategy for mitigating diabetes complications and protecting brain health.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
August 8, 2025 / Madrigal / MASH treatment / Rezdiffra / Liver fibrosis / THR-beta agonist
Madrigal Pharmaceuticals granted equity awards to new employees, supporting its growth in advancing Rezdiffra—currently the only FDA-approved treatment for MASH with fibrosis. The company continues its Phase 3 trial targeting compensated MASH cirrhosis.